$4.9+ Billion Allergy Immunotherapy Market by 2033 with a 10.4% CAGR โ Allied Market Research
Allergy Immunotherapy Market.
Allied Market Research published a report, titled, "Allergy Immunotherapy Market by Type (Subcutaneous Immunotherapy and Sublingual Immunotherapy), Application (Allergy Rhinitis, Asthma, Food Allergy and Others), and Distribution Channel (Hospital Pharmacies, Retail and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the allergy immunotherapy market was valued at $1.8 billion in 2023, and is estimated to reach $4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033.
๐๐๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/A10241
Prime determinants of growth
Rise in prevalence of allergy cases and surge in focus on personalized medicine are the major factors that drive the growth of the allergy immunotherapy market. However, the risk of side effects hinders market growth. Moreover, increase in focus on advancements in immunotherapy treatments offer remunerative opportunities for the expansion of the global allergy immunotherapy market.
Report coverage & details
Report Coverage
Details
Forecast Period
2024โ2033
Base Year
2023
Market Size in 2023
$1.8 billion
Market Size in 2033
$4.9 billion
CAGR
10.4%
No. of Pages in Report
216
Segments Covered
Type, Application, Distribution Channel, and Region.
Drivers
Increase in prevalence of allergies
Rise in focus on personalized medicine
Opportunities
Advancements in immunotherapy treatments
Restraints
Risk of side effects
Segment Highlights
The subcutaneous immunotherapy (SCIT) segment held the highest market share in 2023.
By type Subcutaneous immunotherapy (SCIT) is widely accepted due to its proven efficacy in reducing allergy symptoms and long-term benefits. Administered via regular injections, SCIT gradually desensitizes the immune system to allergens, offering sustained relief even after treatment ends. Its established safety profile, backed by extensive clinical research, makes it a preferred choice among allergists for managing severe allergic conditions.
Prevalence of allergic rhinitis
The rise in the prevalence of allergic rhinitis significantly contributes to the allergy immunotherapy market growth. Increasing cases drive the demand for effective long-term treatments, such as immunotherapy, which offers sustained relief compared to symptomatic treatments, leading to greater adoption and market expansion.
Hospitals pharmacies the major distributors of Allergy immunotherapy
Hospital pharmacies play a crucial role in distributing allergy immunotherapy, ensuring patients receive proper treatment. They dispense allergen extracts, manage inventory, and provide expert guidance on administration. Their accessibility and expertise make them primary sources for patients undergoing allergy treatment, ensuring safe and effective therapy.
Regional Outlook
The allergy immunotherapy market varies significantly by region. In North America and Europe, high healthcare expenditure and advanced medical infrastructure drive market growth, supported by rising allergy prevalence and awareness. In Asia-Pacific, increasing healthcare investments and growing awareness about allergic conditions are expected to boost market demand, while Latin America and the Middle East are gradually adopting these therapies, supported by improving healthcare systems and increased focus on chronic diseases.
Players
Torii Pharmaceutical Co., Ltd.
Biomay AG
ALK-Abello A/S
Allergy Therapeutics
Allovate, LLC
HAL Allergy Group
Jubliant Pharma
Leti Pharma
Merck KGaA
Stallergenes Greer
The report provides a detailed analysis of these key players in the global Allergy immunotherapy market. These players have adopted different strategies such as expansion, product approval, clinical trails, product launch and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Recent Industry Development
In May 2024, ALK-Abellรณ A/S, a pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products, announced the European regulatory filing for ITULAZAX (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for review by the relevant health authorities.
In October 2021, Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announced that the company has entered into an exclusive partnership with Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, for the development of the first of its kind connected device and companion mobile app for patients undergoing Stallergenes Greerโs AIT treatments with sublingual solutions.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ฒ๐ข๐ง๐ : https://www.alliedmarketresearch.com/purchase-enquiry/A10241
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
